First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.